Abeona Therapeutics Inc. (ABEO)
- Previous Close
7.53 - Open
7.50 - Bid 7.54 x 100
- Ask 7.65 x 100
- Day's Range
7.20 - 7.69 - 52 Week Range
2.83 - 9.01 - Volume
386,264 - Avg. Volume
352,966 - Market Cap (intraday)
207.077M - Beta (5Y Monthly) 1.48
- PE Ratio (TTM)
-- - EPS (TTM)
-2.53 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
21.00
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.
www.abeonatherapeutics.comRecent News: ABEO
Performance Overview: ABEO
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ABEO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABEO
Valuation Measures
Market Cap
206.26M
Enterprise Value
159.43M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
46.06
Price/Book (mrq)
13.91
Enterprise Value/Revenue
45.55
Enterprise Value/EBITDA
-3.15
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-46.99%
Return on Equity (ttm)
-260.60%
Revenue (ttm)
3.5M
Net Income Avi to Common (ttm)
-54.19M
Diluted EPS (ttm)
-2.53
Balance Sheet and Cash Flow
Total Cash (mrq)
52.23M
Total Debt/Equity (mrq)
36.42%
Levered Free Cash Flow (ttm)
-18.89M
Research Analysis: ABEO
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell